The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting

被引:0
|
作者
Gardner, Daphne [1 ]
Lakkad, Mrinmayee [2 ]
Qiu, Zhiyu [3 ]
Inoue, Yuta [2 ]
Chandran, Suresh Rama [1 ]
Wherry, Kael [2 ]
机构
[1] Singapore Gen Hosp, Dept Endocrinol, Singapore, Singapore
[2] Medtron Diabet, Northridge, CA USA
[3] Medtron Singapore, Singapore, Singapore
关键词
Advanced hybrid closed-loop system; Cost-effectiveness; Cost of days off work; Type; 1; diabetes; Singapore; DAILY INSULIN INJECTIONS; QUALITY-OF-LIFE; GLYCEMIC CONTROL; PUMP THERAPY; ADULTS; HYPOGLYCEMIA; REIMBURSEMENT; MULTICENTER; VALIDATION; PREVENTION;
D O I
10.1089/dia.2023.0455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite advances in technology, glycemic outcomes in people with type 1 diabetes (T1D) remain suboptimal. The MiniMed 780G (MM780G) advanced hybrid closed-loop (AHCL) system is the latest technology for T1D management with established safety and efficacy. This study explores the cost-effectiveness of MM780G AHCL compared against multiple daily injections (MDI) plus intermittently scanned continuous glucose monitor (isCGM).Methods: A cost-utility analysis was conducted, simulating lifetime outcomes for 1000 T1D individuals, with baseline hemoglobin A1c of 8.4%, using the IQVIA Core Diabetes Model (CDM) v9.5. A Singapore health care payer perspective was taken with 2023 costs applied. Treatment effects were taken from the ADAPT study and treatment-related events from a combination of sources. T1D complication costs were derived from local literature, and health state utilities and disutilities from published literature. Scenario analyses and probabilistic sensitivity analyses (PSAs) explored uncertainty. Cost-effectiveness was assessed based on willingness-to-pay (WTP) thresholds set to Singapore Dollars (SGD) 45,000 (United States Dollars [USD] 33,087) per quality-adjusted life year (QALY) and Singapore's gross domestic product (GDP) per capita of SGD 114,165 (USD 83,941) per QALY.Results: A switch from MDI plus isCGM to MM780G resulted in expected gains in life-years (+0.78) and QALYs (+1.45). Cost savings through reduction in T1D complications (SGD 25,465; USD 18,723) partially offset the higher treatment costs in the AHCL arm (+SGD 74,538; +USD 54,805), resulting in an estimated incremental cost-effectiveness ratio of SGD 33,797 (USD 24,850) per QALY gained. Findings were robust, with PSA outputs indicating 81% and 99% probabilities of cost-effectiveness at the stated WTP thresholds.Conclusion: MM780G is a cost-effective option for people with T1D managed in a Singapore setting.
引用
收藏
页码:324 / 334
页数:11
相关论文
共 50 条
  • [21] Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp
    Ly, Trang T.
    Roy, Anirban
    Grosman, Benyamin
    Shin, John
    Campbell, Alex
    Monirabbasi, Salman
    Liang, Bradley
    von Eyben, Rie
    Shanmugham, Satya
    Clinton, Paula
    Buckingham, Bruce A.
    DIABETES CARE, 2015, 38 (07) : 1205 - 1211
  • [22] Advanced hybrid closed loop compared to standard insulin therapy in type 1 diabetes during delivery and early postpartum
    Beunen, K.
    Van Wilder, N.
    Ballaux, D.
    Vanhaverbeke, G.
    Taes, Y.
    Aers, X. -P.
    Van Huffel, L.
    Marlier, J.
    Lee, D.
    Cuypers, J.
    Preumont, V.
    Siegelaar, S.
    Gillard, P.
    Mathieu, C.
    Benhalima, K.
    DIABETOLOGIA, 2024, 67 : S392 - S393
  • [23] GLYCAEMIC CONTROL AFTER STARTING ADVANCED HYBRID CLOSED-LOOP SYSTEM IN CHILDREN WITH TYPE 1 DIABETES MELLITUS
    Saez Gallego, B.
    Ovejero Garcia, T.
    Garcia De Pablo, I.
    Diaz Martinez, C.
    Diaz Marrero, S.
    Ontoria Betencort, C.
    Espino Sanchez, J. R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A2 - A2
  • [24] RISK OF IMPAIRED AWARENESS HYPOGLYCEMIA IN PATIENTS WITH TYPE 1 DIABETES USERS OF AN ADVANCED HYBRID CLOSED-LOOP SYSTEM
    Nattero-Chavez, L.
    De La Calle, E.
    Bayona, A.
    Ruiz, T.
    Lorenzo, M.
    Izquierdo, A.
    Rodriguez, C. Sanchez
    Corral, M. I.
    Luque-Ramirez, M.
    Pascual, E. Lecumberri
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A123 - A123
  • [25] Advanced Closed-Loop Control System Improves Postprandial Glycemic Control Compared With a Hybrid Closed-Loop System Following Unannounced Meal
    Garcia-Tirado, Jose
    Diaz, Jenny L.
    Esquivel-Zuniga, Rebeca
    Koravi, Chaitanya L. K.
    Corbett, John P.
    Dawson, Martha
    Wakeman, Christian
    Barnett, Charlotte L.
    Oliveri, Mary C.
    Myers, Helen
    Krauthause, Katie
    Breton, Marc D.
    DeBoer, Mark D.
    DIABETES CARE, 2021, 44 (10) : 2379 - 2387
  • [26] Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
    Bergenstal, Richard M.
    Garg, Satish
    Weinzimer, Stuart A.
    Buckingham, Bruce A.
    Bode, Bruce W.
    Tamborlane, William V.
    Kaufman, Francine R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (13): : 1407 - 1408
  • [27] Efficacy of advanced hybrid closed loop systems for the management of type 1 diabetes in children
    Ferrito, Lucia
    Passanisi, Stefano
    Bonfanti, Riccardo
    Cherubini, Valentino
    Minuto, Nicola
    Schiaffini, Riccardo
    Scaramuzza, Andrea
    MINERVA PEDIATRICS, 2021, 73 (06): : 474 - 485
  • [28] Impact on glucometric variables and quality of life of the advanced hybrid closed-loop system in pediatric and adolescent type 1 diabetes
    Lendinez-Jurado, Alfonso
    Gomez-Perea, Ana
    Ariza-Jimenez, Ana B.
    Tapia-Ceballos, Leopoldo
    Becerra-Paz, Icia
    Martos-Lirio, Maria F.
    Moreno-Jabato, Fernando
    Leiva-Gea, Isabel
    JOURNAL OF DIABETES, 2023, 15 (08) : 699 - 708
  • [29] MiniMed™ 780G Advanced Hybrid Closed-Loop System Study in Pregnant Women with Type 1 Diabetes
    Guibert, Clara
    Amoura, Lamia
    Rakotoarisoa, Luc
    Plat, Francoise
    Sonnet, Emmanuel
    Lablanche, Sandrine
    Treglia, Clemence
    Sarde, Elisa
    Leca, Viviane
    Rimareix, Frederique
    Melki, Vincent
    Baucher, Franciane
    Betari, Bouchra
    Meyer, Laurent
    Kessler, Laurence
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (12) : 893 - 901
  • [30] Hybrid closed-loop (HCL) pivotal trial in type 1 diabetes
    Bergenstal, R. M.
    Weinzimer, S. A.
    Brazg, R.
    Bailey, T. S.
    Buckingham, B.
    Garg, S.
    Bode, B.
    Anderson, S. M.
    Slover, R. H.
    Ilany, J.
    Huang, S.
    Welsh, J. B.
    Lee, S. W.
    DIABETOLOGIA, 2016, 59 : S97 - S97